These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease. Tullos NA; Stewart NJ; Davidovich R; Chade AR Nephrol Dial Transplant; 2015 Apr; 30(4):584-93. PubMed ID: 25438341 [TBL] [Abstract][Full Text] [Related]
12. The management of atherosclerotic renovascular disease. Adamczak M; Więcek A Kidney Blood Press Res; 2011; 34(4):277-83. PubMed ID: 21691131 [TBL] [Abstract][Full Text] [Related]
13. Antioxidant intervention blunts renal injury in experimental renovascular disease. Chade AR; Rodriguez-Porcel M; Herrmann J; Zhu X; Grande JP; Napoli C; Lerman A; Lerman LO J Am Soc Nephrol; 2004 Apr; 15(4):958-66. PubMed ID: 15034098 [TBL] [Abstract][Full Text] [Related]
14. Atherosclerotic renovascular disease and renal impairment: can we predict the effect of intervention? Mui KW; Woittiez AJ; Navis G Curr Hypertens Rep; 2007 Apr; 9(2):140-7. PubMed ID: 17442226 [TBL] [Abstract][Full Text] [Related]
19. Renovascular hypertension: is there still a role for stent revascularization? Textor SC Curr Opin Nephrol Hypertens; 2013 Sep; 22(5):525-30. PubMed ID: 23917028 [TBL] [Abstract][Full Text] [Related]
20. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease. Kelsen S; Hall JE; Chade AR Am J Physiol Renal Physiol; 2011 Jul; 301(1):F218-25. PubMed ID: 21478482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]